Patents by Inventor Lynn Hartmann

Lynn Hartmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL COMPOSITIONS AND METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF HUMAN CANCERS
    Publication number: 20120141604
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.
    Type: Application
    Filed: November 4, 2011
    Publication date: June 7, 2012
    Applicants: Millennium Pharmaceuticals, Inc., Mayo Foundation for Medical Education and Research, Board of Regents, The University of Texas System
    Inventors: Edwin Clark, Tallessyn Grenfell-Lee, Karen Lu, Lynn Hartmann, Jeffrey L. Brown, Robert C. Bast, JR., Gordon B. Mills
  • Compositions and methods for the identification, assessment, prevention and therapy of human cancers
    Patent number: 8080368
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: December 20, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Edwin Clark, Tallessyn Grenfell-Lee, Karen Lu, Lynn Hartmann, Jeffrey L. Brown, Robert C. Bast, Jr., Gordon B. Mills
  • NOVEL COMPOSITIONS AND METHODS FOR THE IDENTIFICATION, ASSESSMENT, PREVENTION AND THERAPY OF HUMAN CANCERS
    Publication number: 20110104306
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.
    Type: Application
    Filed: November 30, 2010
    Publication date: May 5, 2011
    Applicants: Millennium Pharmaceuticals, Inc., Board of Regents, The University of Texas System, Mayo Foundation for Medical Education and Research
    Inventors: Edwin Clark, Tallessyn Grenfell-Lee, Karen Lu, Lynn Hartmann, Jeffrey L. Brown
  • Compositions and methods for the identification, assessment, prevention and therapy of human cancers
    Patent number: 7871775
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: January 18, 2011
    Assignees: Millennium Pharmaceuticals, Inc, Mayo Foundation for Medical Edication and Research, Board of Regents, The University of Texas System
    Inventors: Edwin Clark, Tallessyn Grenfell-Lee, Karen Lu, Lynn Hartmann, Jeffrey L. Brown, Robert C. Bast, Jr., Gordon B. Mills
  • Novel compositions and methods for identification, assessment, prevention, and therapy of ovarian cancer
    Publication number: 20090136961
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer.
    Type: Application
    Filed: November 18, 2008
    Publication date: May 28, 2009
    Applicants: Millennium Pharmaceuticals, Inc., Board of Regents, Mayo Foundation for Medical Education and Research
    Inventors: Andrew I. Damokosh, Natalia Lartchouk, James J. Stec, II, Edwin A. Clark, Karen Lu, Lynn Hartmann, Robert C. Bast, JR., Gordon B. Mills
  • Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer
    Patent number: 7470509
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer.
    Type: Grant
    Filed: February 7, 2003
    Date of Patent: December 30, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Andrew I. Damokosh, Natalia Iartchouk, James J. Stec, II, Edwin A. Clark, Karen Lu, Lynn Hartmann, Robert C. Bast, Jr., Gordon B. Mills
  • Novel compositions and methods for the identification, assessment, prevention and therapy of human cancers
    Publication number: 20080286780
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.
    Type: Application
    Filed: December 17, 2007
    Publication date: November 20, 2008
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Edwin Clark, Tallessyn Grenfell-Lee, Karen Lu, Lynn Hartmann, Jeffrey L. Brown
  • Compositions and methods for the identification, assessment, prevention and therapy of human cancers
    Patent number: 7338758
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of “sensitivity markers.” These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.
    Type: Grant
    Filed: February 8, 2002
    Date of Patent: March 4, 2008
    Assignees: Mayo Foundation for Medical Education And Research., Board of Regents, The University of Texas System., Millennium Pharmaceuticals, Inc.
    Inventors: Edwin Clark, Tallessyn Grenfell-Lee, Karen Lu, Lynn Hartmann, Jeffrey L. Brown
  • Novel compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer
    Publication number: 20030180770
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer.
    Type: Application
    Filed: February 7, 2003
    Publication date: September 25, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Andrew I. Damokosh, Natalia Iartchouk, James II Stec, Edwin A. Clark, Karen Lu, Lynn Hartmann
  • Novel compositions and methods for the identification, assessment, prevention and therapy of human cancers
    Publication number: 20030143552
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether tumors are sensitive or resistant to a therapeutic agent. The present invention is also directed to the identification of therapeutic targets. The invention features a number of sensitivity and resistance markers. These are markers that are expressed in most or all cell lines that are sensitive to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are resistant to treatment with that agent. The invention also features a number of “resistance markers.” These are markers that are expressed in most or all cell lines that are resistant to treatment with an agent and which are not expressed (or are expressed at a rather low level) in cells that are sensitive to treatment with that agent. The invention also features marker sets that can predict patients that are likely to respond or not to respond to an agent.
    Type: Application
    Filed: February 8, 2002
    Publication date: July 31, 2003
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Edwin Clark, Tallessyn Grenfell-Lee, Karen Lu, Lynn Hartmann, Jeffrey L. Brown